Skip to main content
/ IR Insights: Recapping our Q3 Earnings...
02 November 2023

IR Insights: Recapping our Q3 Earnings Report

by Moderna
Media Center > Blogs > IR Insights: Recapping our Q3 Earnings Report > image

Earlier today, Moderna reported financial results and provided business updates for the third quarter of 2023. We provided the investor community with an update on our business and clinical updates across oncology, rare and infectious diseases.

Members of our executive team sat down to provide more insight into our financial performance, key milestones, and the exciting developments happening at Moderna. Watch the first installment of our new video series, IR Insights, to hear more from our CEO Stéphane Bancel, President Stephen Hoge, and CFO Jamey Mock:

Stay tuned for more updates and follow us on LinkedIn and Twitter to learn more about Moderna and how we’re changing the future of medicine.

This post and the accompanying video contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna’s expected revenues in future periods; Moderna’s ability to launch multiple products in 2024 and 2025 and return to sales growth in 2025; Moderna’s future cost of sales; Moderna’s expectation to break even in 2026; the sufficiency of Moderna’s current cash balances to fund future plans, and Moderna’s plans not to raise additional equity; Spikevax’s market share and the ability to continue to gain market share; Moderna’s ability to compete in the broader respiratory vaccine commercial market; the anticipated profitability of Moderna’s COVID-19 franchise for 2024 and beyond; Moderna’s anticipated launches of its RSV vaccine in 2024 with a potential best-in-class profile and its COVID + flu combination vaccine in 2025; Moderna’s 2023 through 2025 financial framework; the potential for Moderna to launch up to 15 products in the next five years; the anticipated benefits of combination vaccines; the anticipated initial regulatory approval for mRNA-1083 in 2025; and Moderna’s and Merck’s Phase 3 study of mRNA-4157 in melanoma patients and expected commencement of a Phase 3 trial in NSCLC patients.  The forward-looking statements in this post and video are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at  Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this post.